Just noticed something interesting in Jazz Pharmaceuticals' insider filings. Back in May, Seamus Mulligan—who sits on the board—dropped nearly $10M buying 101,621 shares at around $98 each. That's the kind of move that usually gets my attention. When insiders are putting their own money in, it often signals confidence in where the stock is headed.

Jazz Pharma is an interesting play if you follow biotech. They've got a solid portfolio—Xyrem and Xywav for narcolepsy, Epidiolex for epilepsy, plus oncology drugs like Zepzelca and Vyxeos. The company's sitting on a gross margin around 88%, which is pretty healthy. But there are some headwinds. Revenue growth has been sluggish (down 0.46% in Q1 2025), and their debt-to-equity ratio is elevated at 1.3, which is above sector average.

What caught my eye is the valuation metrics. The P/E ratio of 13.98 is trading below industry average, and the P/S ratio sits at 1.66—both suggesting the market might be underpricing this one. Seamus Mulligan's conviction buy could be betting on a turnaround or upcoming catalysts we haven't fully priced in yet.

That said, insider buying isn't a guarantee. But when you see board members committing serious capital like Seamus Mulligan did, combined with reasonable valuations, it's worth keeping on your radar. Definitely worth digging deeper into their pipeline and upcoming earnings.